<a href="https://laohu8.com/S/NVO">Novo Nordisk</a>, United Biotechnology obesity drug trial shows 19.7% weight lossCOPENHAGEN, Feb 24 (Reuters) - Novo Nordisk NOVOb.CO said on Tuesday its triple agonist UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to 19.7% after 24 weeks in a trial.
(Reporting by Louise Rasmussen, editing by Terje Solsvik)
((terje.solsvik@thomsonreuters.com; +47 918 666 70))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments